Major Program
Supportive Care and Symptom Management
Sponsor
Andrew McDonald
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04743934
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
Intervention
Androgen deprivation therapy, Flibanserin 100 MG, Placebo
Condition
Prostate Adenocarcinoma
Investigators
Andrew McDonald, MD, Amanda Smith, Kate Heinzman